# Pilot Study of FFP104 Dose Escalation in PBC Subjects

> **NCT02193360** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fast Forward Pharmaceuticals** · enrollment: 24 (estimated)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** FFP104

## Key facts

- **NCT ID:** NCT02193360
- **Lead sponsor:** Fast Forward Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2017-08
- **Final completion:** 2017-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2016-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193360, "Pilot Study of FFP104 Dose Escalation in PBC Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02193360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*